Navigation Links
Epilepsy Drug May Relieve Chronic Headaches

Researchers say the drug gabapentin (Neurontin) taken at 2,400 milligrams a day is an effective preventive measure // for people with chronic daily headaches.
Gabapentin is an approved anti-epileptic drug. Studies have also shown its success in treating other pain-related health issues like diabetic neuropathy, postherpetic neuralgia, and migraine headache. Since gabapentin often reduces migraines by more than 50 percent and chronic daily headaches often have migraine-like features, researchers in Australia conducted a double-blind, placebo-controlled study to determine the drug's specific effect on chronic daily headaches. This type of study is the gold standard of clinical research studies where neither the researchers nor the participants know who received the drug or an identical dummy substance, called a placebo.

For the study researchers recruited 133 patients who had headaches at least 15 days every month that lasted more than four hours at a time. The patients were randomly selected to receive gabapentin or a placebo for six weeks. After that period, none of the patients received either treatment for a week, and then each group switched to the opposite treatment for a second six weeks.

Results showed 36 percent of the patients taking 2,400 milligrams of gabapentin a day stopped having chronic daily headaches. Negative effects of the drug included vomiting, dizziness, dysarthria (problems speaking), sleepiness, and constipation.
'"/>




Page: 1

Related medicine news :

1. General Anesthesia Safe For Children On Ketogenic Diet Suffering From Epilepsy
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Epilepsy can be predicted
4. Epilepsy Drugs Can Enhance Risk of Birth Defects
5. Epilepsy Drug Helps Diabetic Nerve Damage
6. More Complications Seen In Women With Epilepsy
7. Epilepsy Drugs Found To Lead To Bone Loss
8. Another Use For Epilepsy Drugs
9. Epilepsy Patients Could Benefit From Pacemakers
10. Early Surgery For Treatment Of Epilepsy Questioned
11. Epilepsy Drug Valproate and Lamotrigine Linked To Malformed Fetus
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... Los Angeles, CA (PRWEB) , ... April 29, 2016 , ... ... Sarah Mirmelli, a mother and divorcee, shares her enthusiasm for Botox and lip injections, ... of the world famous youth oriented Coachella Valley Music and Arts Festival. The article ...
(Date:4/29/2016)... ... April 29, 2016 , ... Our bodies are bombarded daily by ... and deal with these stressors is to adopt a more healthful diet, but too ... Risa Groux, a certified Holistic Nutritionist and the creator of the Newport Beach Cleanse ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... student loans more flexibility in repaying their loans, more information about their loan ... time when total outstanding student loan debt, including federal and private loans, has ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Spine Team Texas, ... is proud to announce one of their physicians has been invited to be a ... (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... Canadian Celiac Association (CCA), is pleased to announce the launch of the ... nutritional articles, recipes, and more. The purpose of the GFCP Scoop ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... TOKYO , April 28, 2016 ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for ... and Pharmacovigilance team to bring a wealth of insight to a ... unparalleled pharmacovigilance knowledge. George Phillips joined ArisGlobal ...
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/27/2016)... Inc. (Nasdaq: HOLX ) announced today ... quarter ended March 26, 2016.  GAAP diluted earnings ... non-GAAP diluted EPS of $0.47 increased 14.6%.  Revenue ... basis, and 6.3% on a constant currency basis.  ... highlighted by 14.6% growth in non-GAAP EPS," said ...
Breaking Medicine Technology: